Erasca (ERAS) vs Genmab A/S (GMAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Erasca (ERAS) has outperformed Genmab A/S (GMAB) over the past year, gaining 536.2% versus a gain of 10.1%. Over five years, ERAS leads with a -13.1% price change compared with -18.9% for GMAB. Genmab A/S is the larger company by market cap ($22.17 billion vs $5.41 billion), about 4.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | GMAB |
|---|---|---|
| Share price | $15.46 | $36.05 |
| Market cap | $5.41B | $22.17B |
| 1-day change | +9.49% | -1.64% |
| YTD return | +315.59% | +17.05% |
| 1-year return | +536.21% | +10.11% |
| 5-year return | -13.15% | -18.86% |
| P/E ratio (TTM) | — | 28.39 |
| Forward P/E | — | 23.64 |
| EPS (TTM) | $-0.95 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.72B |
| Revenue growth (YoY) | — | +19.19% |
| Net income (latest FY) | $-124.55M | $963.00M |
| Gross margin | — | 93.60% |
| Operating margin | — | 28.63% |
| Net margin | — | 25.89% |
| 52-week high | $24.28 | $40.17 |
| 52-week low | $2.11 | $23.62 |
| Distance from 52-week high | -36.33% | -10.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +55.95% | +19.89% |
| Average volume | 4.37M | 2.83M |
| Shares outstanding | 349.76M | 614.90M |
| Employees | 103 | 3,119 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S is about 4.1 times larger than Erasca by market value ($22.17B vs $5.41B).
- ERAS has outperformed GMAB by 526.1 percentage points over the past year.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
ERAS vs GMAB FAQ
Which is bigger, Erasca or Genmab A/S?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.17B compared with $5.41B for Erasca (ERAS).
Which stock has performed better over the past year, ERAS or GMAB?
ERAS returned +536.21% over the past 12 months, compared with +10.11% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and Genmab A/S in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.